DRNA vs KIN

Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Kindred Biosciences, Inc.

Kindred Biosciences, Inc., a commercial-stage biopharmaceutical company, engages in developing therapies for pets. Its product pipeline focuses on biologics for a range of indications primarily in dogs and cats. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats; and Zimeta, a dipyrone injection for the control of fever in horses. It also develops KIND-016, a monoclonal antibody for the treatment of atopic dermatitis in dogs; KIND-032, a monoclonal antibody targeting interleukin-4 (IL-4) receptor for the treatment of atopic dermatitis in dogs; KIND-025 a canine fusion protein targeting IL-4 and IL-13 for atopic dermatitis in dogs; KIND-030, a monoclonal antibody targeting canine parvovirus for the prophylactic indication in dogs; KIND-509, an antibody for canine inflammatory bowel disease in dogs; KIND-510a, a long-acting feline recombinant erythropoietin being developed for the management of non-regenerative anemia in cats; and KIND-511, an anti-tumor necrosis factor treatment for newborn foals. The company was incorporated in 2012 and is headquartered in Burlingame, California.